A5093529055- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Protease and Inhibitor Mechanisms
- Renal and related cancers
- Cancer Cells and Metastasis
- Cardiac Structural Anomalies and Repair
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
Université Libre de Bruxelles
2023-2024
Pancreatic ductal adenocarcinoma (PDAC) represents a formidable challenge due to its aggressive nature and poor prognosis. The tumor microenvironment (TME) in PDAC, characterized by intense stromal desmoplastic reactions dominant presence of cancer-associated fibroblasts (CAFs), significantly contributes therapeutic resistance. However, within the heterogeneous CAF population, fibroblast activation protein (FAP) emerges as promising target for Gallium-68 FAP inhibitor positron emission...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for treatment localized PDAC. However, histo-molecular effects iHD-SBRT are still poorly explored. In this study, we have shown that TNT, associating FOLFIRINOX [FFX] followed by iHD-SBRT,...